

















Esophageal Oncology group : Treatment map Mar.2020.

Subject (UICC 7th)	Standard treatment in Japan	Trials ongoing or follow up
Stage IA	<p>Endoscopic mucosal resection(ESD/EMR) + CRT</p> <p>Esophagectomy¹⁾ </p> <p>JCOG0502 Concurrent chemoradiotherapy </p>	<p>JCOG1904 CRT(IFI⁵⁾ vs.CRT (ENI⁶⁾) 2020/03 ~ Ongoing </p> <p>JCOG1409 Open esophagectomy vs. Thoracoscopic Esophagectomy 2015.5 Ongoing </p>
Stage IB	<p>JCOG9907 Neoadjuvant chemotherapy (CDDP+ 5-FU) (NeoCF) +Esophagectomy¹⁾ </p> <p>JCOG0909 Concurrent chemoradiotherapy (CF-RT) (+Salvage surgery) (+Salvage ER) </p>	<p>JCOG1109 Neo CF²⁾ vs. Neo DCF³⁾ vs. Neo CF-RT⁴⁾ +Esophagectomy¹⁾ 2012/12 ~ Follow up period </p> <p>JCOG1804E Neo CF²⁾ or Neo DCF³⁾ +Nivolumab +Esophagectomy¹⁾ 2019/3 ~ Ongoing </p>
Stage II		
Stage III		
T4a/M1LYM Resectable	<p>Neo CF+esophagectomy¹⁾ or Neo CF-RT+esophagectomy¹⁾ </p> <p>Concurrent chemoradiotherapy </p>	<p>JCOG1510 : Concurrent chemoradiotherapy vs. Induction DCF+ Concurrent chemoradiotherapy (or+esophagectomy¹⁾) 2018.2 ~ Ongoing </p>
T4b/M1LYM Unresectable	<p>Unresectable : Concurrent chemoradiotherapy JCOG9516, JCOG9908, JCOG0303, KROSG0101 </p>	
Stage IV	<p>1st line chemotherapy: CDDP+5-FU JCOG8807, JCOG9407, JCOG9905-DI </p> <p>2nd line chemotherapy: Nivolumab </p> <p>3rd line chemotherapy: Paclitaxel, Docetaxel </p>	<p>JCOG1314 (1st line) CDDP+ 5-FU vs. biweekly DOC+CDDP+5-FU 2014/9 Ongoing </p>
Recurrent		

1) Esophagectomy+2-3 field lymph node dissection 2) CF : CDDP+5-FU 3)DCF : DOC+CDDP+5-FU 4)CF-RT : CDDP+5-FU+radiation therapy 5) Involved Field Irradiation 6) Elective Lymph node Irradiation